Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
10 evidence topics · 11 sources
Maximal TYK2 inhibition over 24 hours with twice-daily dosing
“Indeed, preclinical and phase 1 studies demonstrated that envudeucitinib twice daily achieves maximal TYK2 target inhibition (90% inhibitory concentration [IC90]) at clinically relevant doses over 24 h” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical inhibition of STAT phosphorylation and interferon-gamma production
“Additionally, ESK‐001 significantly inhibited STAT phosphorylation and downstream IFNγ production stimulated by IL‐12, IL‐23, and IFNα in human whole blood and peripheral blood mononuclear cells in a concentration‐dependent manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood biomarkers of TYK2 inhibition in healthy participants
“ESK‐001 inhibited the downstream TYK2 pathway as shown by inhibition of pSTAT1 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Transcriptomic analysis of unstimulated whole blood samples confirmed dose‐dependent inhibition of Type I IFN‐induced genes and SIGLEC1, a novel TYK2‐responsive biomarker.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By correlating PK exposure data with PD readouts, a strong PK/PD relationship was demonstrated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote